Glycosylated RGD multivalent ligand radiomolecules, their radionuclide-labeled complexes, their preparation methods and applications

By linking glucose-modified RGD polypeptide units to TRAP chelating agents, a radioactive molecule with synergistic effects of multivalent and glycosylation is formed, solving the problems of unsatisfactory in vivo pharmacokinetics and poor blood-brain barrier penetration of RGD probes. This enables high-contrast imaging of central nervous system tumors and potential integrated diagnostic and therapeutic applications.

CN123106840APending Publication Date: 2026-11-17SICHUAN UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611623736.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing RGD-type radioactive probes have unsatisfactory pharmacokinetics in vivo, high non-specific renal uptake, and difficulty in penetrating the blood-brain barrier, which limits their application in central nervous system tumor imaging.

Method used

Using TRAP chelating agent as the core framework, glucose-modified RGD polypeptide units are linked to the ends of its three branches through click chemistry to form a symmetrical trimer structure. Compound A is prepared by combining 68Ga, 177Lu or 161Tb radionuclides, and its pharmacokinetic behavior is optimized through specific reaction conditions.

Benefits of technology

It significantly reduces non-specific uptake by the kidneys, improves the contrast between tumors and background, and enables high-contrast PET/CT imaging of central nervous system tumors such as gliomas, providing potential for integrated diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106840A_ABST
    Figure CN123106840A_ABST
Patent Text Reader

Abstract

This invention provides a glycosylated RGD multivalent ligand radiomolecule, its radionuclide-labeled complex, its preparation method, and its applications, belonging to the field of biomedical technology. This invention provides an RGD multivalent ligand radiomolecule based on a TRAP chelating agent and glucose modification. Glycosylation modification effectively regulates the in vivo distribution behavior of the probe, significantly reduces non-specific renal uptake, improves tumor-background contrast, and endows the probe with the ability to penetrate the blood-brain barrier, achieving high-contrast PET / CT imaging of central nervous system tumors such as gliomas. This probe has a high labeling rate and good stability, and has broad application prospects in molecular imaging and potential radiotherapy of integrin αvβ3-positive tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to glycosylated RGD multivalent ligand radioactive molecules, their radionuclide-labeled complexes, their preparation methods, and their applications. Background Technology

[0002] Integrins are a class of transmembrane glycoprotein receptors involved in various physiological processes such as cell adhesion, migration, proliferation, and angiogenesis. Integrin αvβ3, in particular, is upregulated on the surface of neovascular endothelial cells in various solid tumors and some tumor cells, while its expression level is low in normal tissues, making it an important biomarker for tumor molecular imaging and targeted therapy. Peptides containing the arginine-glycine-aspartic acid (RGD) sequence can specifically recognize integrin αvβ3, and RGD-based radioactive probes have been widely used for early tumor diagnosis and efficacy evaluation.

[0003] Existing technologies have developed various RGD-type radioimaging agents, including monomeric, dimeric, and multimeric forms. Polymerization strategies can significantly enhance binding affinity to integrin receptors through multivalent effects, thereby increasing tumor uptake. Regarding chelating agents, NOTA, DOTA, and TRAP have all been used to label radionuclides. Although several RGD probes have entered preclinical studies, these probes still face some common problems when used in vivo. For example, most RGD probes are rapidly excreted by the kidneys, leading to high non-specific renal uptake, which not only affects target / non-target contrast but may also increase the risk of radiation damage. Furthermore, due to the blood-brain barrier, traditional RGD probes have difficulty effectively penetrating the brain parenchyma, limiting their application in imaging central nervous system tumors such as gliomas. Therefore, optimizing the pharmacokinetic behavior of RGD probes through molecular engineering, reducing uptake in non-target organs, and expanding their application in central nervous system diseases are among the research hotspots in this field. Summary of the Invention

[0004] The purpose of this invention is to provide glycosylated RGD multivalent ligand radioactive molecules, their radionuclide-labeled complexes, their preparation methods, and applications, thereby solving the technical problems of existing RGD-type radioactive probes, such as unsatisfactory in vivo pharmacokinetics, high non-specific renal uptake, and difficulty in penetrating the blood-brain barrier to achieve imaging of central nervous system tumors.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a compound, which is compound A or a pharmaceutically acceptable salt thereof, wherein compound A has the following structure: a TRAP chelating agent as the core backbone, wherein each of the three branches of the TRAP chelating agent is connected to a glucose-modified RGD polypeptide unit via a triazole ring, wherein the TRAP chelating agent is triazacyclononane-trimethylenephosphonic acid, and the glucose modification is to attach a 2-azidoglucose group to a lysine residue of the RGD polypeptide; The RGD polypeptide is a cyclic polypeptide containing the amino acid sequence shown in SEQ ID NO:1; The compound A has the structure shown in Formula I:

[0006] Preferably, compound A has a structure as shown in Formula I: Formula I.

[0007] The present invention also provides a radionuclide-labeled complex, characterized in that the complex is formed by coordination between the above-mentioned compound and a radionuclide, wherein the radionuclide is selected from... 68 Ga、 177 Lu or 161 At least one of Tb.

[0008] The RGD peptide and isothiazolone were dissolved in a mixed solution of water and acetonitrile. After stirring and reacting, trifluoroacetic acid was added, and sodium 2-azidoglucose sulfinate and TBHP were added under an inert gas atmosphere to obtain the 2N3-Glu-RGD intermediate. Under inert gas protection, the 2N3-Glu-RGD intermediate and the TRAP chelating agent were reacted with a copper catalyst and ligand at 60-80°C for 8-12 h to carry out a click cycloaddition reaction to generate the compound.

[0009] Preferably, the TRAP chelating agent is prepared by a method comprising the following steps: 1,4,7-triazacyclononane and 3-(hydroxyphosphono)propionic acid are dissolved in hydrochloric acid aqueous solution, heated to 60-80°C, and paraformaldehyde is added stepwise over 18-30 h. The TRAP intermediate is obtained after purification by ion exchange resin. The TRAP intermediate and DIPEA were dissolved in DMSO, HATU and propargylamine were added, and the mixture was stirred at 30-40°C for 20-40 min. Then, trifluoroacetic acid aqueous solution was added to precipitate the solid, which was purified by HPLC to obtain the TRAP chelating agent. The sodium 2-azidoglucose sulfinate is obtained by a preparation method including the following steps: reacting a starting glucose intermediate with chloroacetyl chloride at 20-30°C for 1-3 h in the presence of dichloromethane and triethylamine to obtain intermediate product 1; The intermediate product 1 was reacted with sodium azide in DMF at 20-30°C for 2-4 h to obtain intermediate product 2; The intermediate product 2 was reacted with methyl mercaptopropionate at 20-30°C for 2-4 h under BF3·Et2O catalysis to obtain intermediate product 3; mCPBA was added at 0~5℃, and then the temperature was restored to 20~30℃ for 2~4 h to oxidize intermediate 3 to intermediate 4. The intermediate product 4 was reacted in the presence of MeONa at 20-30°C for 1-3 h to remove the acetyl protecting group, yielding sodium 2-azidoglucose sulfinate. The specific conditions for reacting sodium 2-azidoglucose sulfinate with the RGD polypeptide are as follows: the RGD polypeptide is dissolved in a mixed solution of water and acetonitrile, stirred for 5-15 min, trifluoroacetic acid is added, sodium 2-azidoglucose sulfinate and TBHP are added under an inert gas environment, and the reaction is carried out at 20-30℃ for 4-8 h. Then, the intermediate 2N3-Glu-RGD is obtained by HPLC purification. The solvent for the click cycloaddition reaction is a mixed solution of tert-butanol, water, and DMF, with a volume ratio of 0.5~1.5:0.5~1.5:0.5~1.5. The click cycloaddition reaction further includes a copper removal purification step: DTPA is added to the reaction product, the pH is adjusted to 2.0~2.5 with hydrochloric acid, the reaction is heated to 50~70℃ for 0.5~2 h, and then preparative HPLC purification is performed.

[0010] Preferably, the reaction includes the following steps: dissolving the above compound, adjusting the pH of the reaction system to 2.5-4.5 using sodium acetate solution, adding a radionuclide solution, and heating the reaction at 70-90°C for 10-30 min to obtain the radionuclide-labeled complex.

[0011] The present invention also provides a pharmaceutical composition comprising the above-described compound or a radiolabeled complex, and a pharmaceutically acceptable carrier.

[0012] The present invention also provides the use of the above-mentioned compounds or radionuclide-labeled complexes in the preparation of imaging agents for tumor-targeted imaging.

[0013] The present invention also provides the application of the above-mentioned radionuclide-labeled complex in the preparation of a drug for targeted radiotherapy of tumors.

[0014] The beneficial effects of this invention are: This invention provides a RGD multivalent ligand radiomolecule based on a TRAP chelating agent and glucose modification. Glycosylation modification effectively regulates the in vivo distribution behavior of the probe, significantly reduces non-specific renal uptake, improves tumor-background contrast, and endows the probe with the ability to penetrate the blood-brain barrier, achieving high-contrast PET / CT imaging of central nervous system tumors such as gliomas. This probe exhibits high labeling efficiency and good stability, showing broad application prospects in molecular imaging and potential radiotherapy of integrin αvβ3-positive tumors.

[0015] Specifically, the present invention has the following advantages: Advantages of the compound structure design: This invention uses a TRAP chelating agent as the core framework, and through click chemistry, attaches a glucose-modified RGD polypeptide unit to the end of each of its three branches to form a symmetrical trimer structure. This design achieves high affinity binding to the integrin αvβ3 receptor using multivalent RGD units (the multivalent effect increases affinity by 1-2 orders of magnitude compared to monomers), and significantly improves the molecule's hydrophilicity and spatial conformation through glycosylation modification, laying a structural foundation for subsequent pharmacokinetic optimization.

[0016] The radionuclide-labeled complexes provided by this invention exhibit excellent performance: 68 The Ga-Trap (Glu-RGD)3 complex has a radiochemical purity of over 99.8% (see...). Figure 6 After incubation in phosphate buffer (pH 7.4) and fetal bovine serum for 120 min, the radiochemical purity remained above 99.50% and 99.34%, respectively (see [link to relevant documentation]). Figure 7 This indicates that the labeled product has extremely high coordination efficiency and in vitro stability, and can be used in in vivo experiments without further purification, solving the problems of easy label removal and poor stability of the labeled product in the prior art.

[0017] The preparation method is simple and efficient: the synthetic route of the precursor compounds in this invention is clear, and each intermediate is purified by preparative HPLC, with controllable overall yield; the radiolabeling step only requires mixing the precursor with... 68 The GaCl3 solution can be reacted at pH 3.0–4.0 and 80°C for 20 minutes, requiring no subsequent purification. The labeling yield is stable, the operation is simple, and it is suitable for rapid clinical preparation. Furthermore, this method can be extended to… 177 Lu、 161 Labeling with therapeutic radionuclides such as Tb enables integrated diagnosis and treatment.

[0018] Significantly improved in vivo pharmacokinetics: compared with the unglycosylated control probe [ 68Compared to Ga-Trap(RGD)3, the probe of this invention showed approximately 17% higher tumor uptake and approximately 47% lower renal uptake in tumor-bearing mice at 60 min, and an approximately 128% higher tumor / kidney ratio (see [link to original text]). Figure 11 (and in vivo distribution data). Meanwhile, the probe maintained tumor uptake at 4.78–5.62% ID / g at 120 min, demonstrating good tumor retention capacity and providing a sufficient time window for radiotherapy.

[0019] Breaking through the blood-brain barrier to achieve specific imaging of gliomas: The probe of this invention can effectively penetrate the blood-brain barrier in a U87MG orthotopic glioma model, showing significant radioactive enrichment at the tumor site, while normal brain tissue shows extremely low uptake, resulting in high-contrast PET / CT images (see...). Figure 9 This feature overcomes the technical bottleneck of traditional RGD probes being difficult to use for central nervous system tumor imaging, providing a new tool for the early diagnosis and accurate assessment of gliomas.

[0020] High targeting specificity and low non-target toxicity: Blocking imaging results show that pre-injection of an excessive amount of c(RGDfK) peptide can reduce tumor uptake by 50%–70% (see...). Figure 10 This demonstrates that the probe's tumor enrichment primarily depends on the specific recognition of integrin αvβ3. Simultaneously, the significantly reduced renal uptake leads to a substantial decrease in the potential risk of renal radiation toxicity, thus improving the probe's safety for clinical translation.

[0021] Wide range of applications and potential for integrated diagnosis and treatment: The compounds of this invention can be labeled 68 Ga is used in PET / CT imaging and can also be used for marking. 177 Lu or 161 Tb is used for targeted radiotherapy, enabling integrated diagnostic and therapeutic applications using the same molecular structure. This probe is suitable for various solid tumors with high integrin αvβ3 expression (such as glioma, melanoma, breast cancer, lung cancer, etc.), and has unique advantages, especially in the imaging of central nervous system tumors.

[0022] Stability and convenience of the pharmaceutical composition: The compounds or radiolabeled complexes of the present invention can be formulated into lyophilized powder injections with pharmaceutically acceptable carriers (such as physiological saline, phosphate buffer, mannitol, etc.), and can be rapidly labeled with radionuclide solution before use, which facilitates storage, transportation and immediate clinical use. Attached Figure Description

[0023] Figure 1 Here is the chemical structure diagram of Trap(Glu-RGD)3 synthesized in this invention; Figure 2 Synthetic route for TRAP chelating agents; Figure 3The synthetic route for sodium 2-azidoglucose sulfinate; Figure 4 The 2N3-Glu-RGD synthesis route is used. Figure 5 The synthetic route for Trap(Glu-RGD)3; Figure 6 for[ 68 High performance liquid chromatography (HPLC) chromatogram (A) and radio high performance liquid chromatography (Radio-HPLC) chromatogram (B) of Ga-Trap(Glu-RGD)3. Figure 7 for[ 68 Figure 1 shows the results of the in vitro stability evaluation of Ga-Trap (Glu-RGD)3 in phosphate buffered solution (PBS, pH = 7.4) (A) and fetal bovine serum (FBS) (B); Figure 8 for[ 68 PET / CT imaging of Ga-Trap (Glu-RGD)3 in U87MG human glioma subcutaneously tumor-bearing mice (A) and analysis results of semi-quantitative radiometric parameters (%ID / g) of tumor and major tissues (n=3) (B). Dashed lines indicate tumor location; Figure 9 for[ 68 PET / CT imaging of Ga-Trap (Glu-RGD)3 in U87MG human glioma-bearing mice (A) and analysis results of semi-quantitative radiometric parameters (%ID / g) of tumor and major tissues (n=3) (B). Dashed lines and arrows indicate tumor location; Figure 10 for[ 68 Ga-Trap (Glu-RGD)3 blocking PET / CT imaging in U87MG glioma subcutaneous tumor-bearing mice (A) and the results of semi-quantitative radiometric parameters (%ID / g) of the tumor, with blocking and non-blocking analysis (n=3) (B). Dashed lines indicate tumor location, **** indicates p <0.0001; Figure 11 for[ 68 In vivo biodistribution of Ga]Ga-Trap(Glu-RGD)3 in U87MG human glioma-bearing mice (n=3); Figure 12 This is the high-resolution electrospray mass spectrometry (HRMS, ESI-TOF) spectrum of Trap(Glu-RGD)3. Detailed Implementation

[0024] The present invention provides a compound, wherein the compound is compound A or a pharmaceutically acceptable salt thereof, wherein compound A has the following structure: a TRAP chelating agent as the core backbone, wherein each of the three branches of the TRAP chelating agent is connected to a glucose-modified RGD polypeptide unit via a triazole ring.

[0025] In this invention, the TRAP chelating agent refers to triazacyclononane-trimethylene phosphonic acid, which has a triazacyclononane core and three identical phosphonic acid side arms, and is capable of reacting with various trivalent metal ions (such as...). 68 Ga、 177 Lu、 161 TRAP chelators form stable complexes with Tb, etc. TRAP chelators have wide applications in radiopharmaceuticals; their coordination reactions with metal nuclides can be rapidly completed under mild conditions, and the resulting complexes exhibit high in vitro and in vivo stability. The "triazole ring" is a five-membered heterocyclic structure formed by a copper-catalyzed click cycloaddition reaction (CuAAC) between an azide group and an alkyne group. This reaction has advantages such as high yield, good selectivity, and mild reaction conditions, and is a commonly used bioorthogonal reaction for linking molecular fragments. The "glucosyl-modified RGD polypeptide unit" refers to a glucose group covalently linked to a specific amino acid residue (usually the ε-amino group of lysine) of the RGD polypeptide. Glycosylation can significantly alter the molecule's hydrophilicity, charge distribution, and spatial conformation, thereby optimizing its pharmacokinetic behavior in vivo. The RGD polypeptide contains an arginine-glycine-aspartic acid (Arg-Gly-Asp) sequence and can specifically recognize and bind to the integrin αvβ3 receptor, which is highly expressed on the surface of various tumor neovascular endothelial cells and tumor cells. The term "pharmaceutically acceptable salt" refers to a pharmacologically acceptable salt formed by the compound of the present invention with an acid or base, such as hydrochloride, sulfate, phosphate, acetate, citrate, tartrate, methanesulfonate, etc., which does not alter the biological activity of the compound and is suitable for pharmaceutical formulation.

[0026] Preferably, the TRAP chelating agent is triazacyclononane-trimethylenephosphonic acid, the glucose modification is to attach a 2-azidoglucose group to the lysine residue of the RGD polypeptide, and the RGD polypeptide is a cyclic polypeptide c(RGDfK) containing the amino acid sequence shown in SEQ ID NO:1.

[0027] As a further preferred embodiment, the cyclic RGD polypeptide refers to a cyclic peptide formed by cyclizing a linear RGD polypeptide through head- and tail amide bonds. Cycling can increase the conformational rigidity of the polypeptide, improve its resistance to proteases, and thus prolong its in vivo half-life. The azido group (-N3) in the 2-azidoglucose group is a commonly used reactive group in click chemistry and can undergo a cycloaddition reaction with an alkynyl group. The amino acid sequence shown in SEQ ID NO:1 is a cyclic pentapeptide sequence designed and verified by the inventors. Specific sequence information can be found in the sequence listing. The polypeptide encoded by this sequence can bind integrin αvβ3 with high affinity.

[0028] Preferably, compound A has the structure shown in Formula I as described above, in Figure 1 As shown in the figure. The compound represented by Formula I is the most preferred specific compound of the present invention, and its molecular formula, molecular weight, and high-resolution mass spectrometry data can be confirmed by the characterization data in the examples. In this structural formula, the TRAP core is linked to a glucose-modified cyclic RGD pentapeptide through three phosphonic acid branch ends of triazole rings, forming a symmetrical trimer structure. This structural design achieves a synergistic effect of multivalent and glycosylation.

[0029] The present invention also provides a radionuclide-labeled complex, characterized in that the complex is formed by coordination between the above-mentioned compound and a radionuclide, wherein the radionuclide is selected from... 68 Ga、 177 Lu or 161 At least one of Tb.

[0030] In this invention, the radionuclide 68 Ga is a positron-emitting nuclide with a half-life of 68 minutes, suitable for positron emission tomography (PET / CT) imaging. 68 Ge / 68 Ga generators are readily available. 177 Lu is a β-emitting therapeutic radionuclide with a half-life of 6.65 days. It also emits gamma rays that can be used for SPECT imaging and is one of the most commonly used radionuclides in current radionuclide therapy. 161 Tb is also a promising therapeutic radionuclide, with decay properties similar to... 177 Lu is similar but has a different energy spectrum. The coordination reaction between TRAP chelating agents and these nuclides is usually carried out under weakly acidic to neutral conditions. The reaction is rapid, does not require high temperatures, and does not damage the peptide structure. The labeled complexes have high specific activity and radiochemical purity, and can be directly used for in vivo imaging or therapy.

[0031] The present invention also provides a method for preparing the above-mentioned compound, comprising the following steps: synthesizing sodium 2-azidoglucose sulfinate; dissolving the RGD polypeptide and isothiazolone in a mixed solution of water and acetonitrile, stirring and reacting (to couple the RGD polypeptide and isothiazolone), adding trifluoroacetic acid, and adding sodium 2-azidoglucose sulfinate and TBHP under an inert gas environment to obtain a 2N3-Glu-RGD intermediate; under an inert gas protection, reacting the 2N3-Glu-RGD intermediate with a TRAP chelating agent in the presence of a copper catalyst and ligand at 60-80°C for 8-12 h to perform a click cycloaddition reaction to generate the compound.

[0032] In this preparation method, the specific operation of "synthesizing sodium 2-azidoglucose sulfinate" can be carried out using conventional saccharochemistry methods in the art, such as introducing azido and sulfinic acid groups from glucose derivatives through a multi-step reaction. The isothiazolone is used to form disulfide bonds with the free thiol groups of the polypeptide, thereby carrying out further free radical reactions. "TBHP" is tert-butyl hydroperoxide, a commonly used oxidant and free radical initiator. The volume ratio of the "mixed solution of water and acetonitrile" can vary over a wide range, for example, from 1:1 to 1:3, preferably 1:2. The reaction temperature can be selected within a narrower range, for example, 65~75℃, most preferably 70℃; the reaction time can be 9~11 h, most preferably 10 h. Inert gas protection is typically achieved using nitrogen or argon to prevent oxygen in the reaction system from interfering with the click reaction. The copper catalyst can be a Cu(I) salt such as [Cu(MeCN)4]PF6, or a Cu(II) salt with a reducing agent to generate Cu(I) in situ; the ligand is usually a nitrogen-containing heterocyclic compound such as TBTA or THPTA, used to stabilize Cu(I) and accelerate the reaction.

[0033] Preferably, the TRAP chelating agent is prepared by a method comprising the following steps: dissolving compound 1,4,7-triazacyclononane and 3-(hydroxyphosphono)propionic acid in an aqueous hydrochloric acid solution, heating to 60-80°C, adding paraformaldehyde stepwise over 18-30 h, and purifying with an ion exchange resin to obtain a TRAP intermediate; dissolving the TRAP intermediate and DIPEA in DMSO, adding HATU and propargylamine, stirring at 30-40°C for 20-40 min, then adding an aqueous trifluoroacetic acid solution to precipitate a solid, which is then purified by preparative HPLC to obtain the TRAP chelating agent; wherein the concentration of the aqueous hydrochloric acid solution can be 1-6 M, preferably 6 M. The heating temperature can be further preferably 65-75°C, more preferably 70°C; the heating time is preferably 20-28 h, more preferably 24 h. The stepwise addition of paraformaldehyde can control the reaction rate and avoid excessively high local concentrations. Dowex 50 wx8 ion exchange resin is a strong acidic cation exchange resin used to remove metal ions and basic impurities in the reaction. DIPEA is N,N-diisopropylethylamine, a commonly used organic base; DMSO is dimethyl sulfoxide, a polar aprotic solvent; HATU is 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, a commonly used condensing agent used to activate the coupling of carboxyl and amine groups; the stirring temperature is preferably 32~38℃, more preferably 37℃; the stirring time is preferably 25~35 min, more preferably 30 min. The concentration of trifluoroacetic acid aqueous solution is usually 1%~10%, used to adjust the pH to precipitate the product. Preparation and purification are performed using a reversed-phase column with acetonitrile / water as the mobile phase. The target fraction is collected and lyophilized to obtain the pure product.

[0034] The sodium 2-azidoglucose sulfinate is obtained by a preparation method comprising the following steps: reacting a starting glucose intermediate with chloroacetyl chloride at 20-30°C for 1-3 h in the presence of dichloromethane and triethylamine to obtain intermediate 1; reacting intermediate 1 with sodium azide in DMF at 20-30°C for 2-4 h to obtain intermediate 2; reacting intermediate 2 with methyl mercaptopropionate at 20-30°C for 2-4 h under BF3·Et2O catalysis to obtain intermediate 3; adding mCPBA at 0-5°C, and then restoring the temperature to 20-30°C for 2-4 h to oxidize intermediate 3 to intermediate 4; reacting intermediate 4 with MeONa at 20-30°C for 1-3 h to remove the acetyl protecting group, thereby obtaining sodium 2-azidoglucose sulfinate.

[0035] In the above multi-step synthesis, the starting glucose intermediate can be 1,2,3,4-tetra-O-acetyl-β-D-pyranose glucose or other protected forms of glucose. Chloroacetyl chloride is used to introduce a chloroacetyl group onto the sugar ring; triethylamine acts as an acid-binding agent to absorb the generated hydrogen chloride. Dichloromethane (DCM) is an inert solvent, and excess reagent is removed by washing after the reaction. Sodium azide (NaN3) is used for nucleophilic substitution to replace the chlorine atom with an azide group; DMF is a polar solvent, which favors SN2 reactions. BF3·Et2O is a Lewis acid catalyst used to catalyze the addition of methyl mercaptopropionate to the sugar group. mCPBA, m-chloroperoxybenzoic acid, is a commonly used peroxy acid oxidant that oxidizes thioethers to sulfones. MeONa, sodium methoxide, is a strong base used to remove the acetyl protecting group from the sugar ring. The reaction progress can be monitored by thin-layer chromatography (TLC) or LCMS. After the reaction is complete, the intermediate is purified by extraction, washing, column chromatography, or preparative HPLC. The temperature range mentioned above can be further preferably 22~28℃, more preferably 25℃; the time for each step can be further preferably 1.5~2.5 h, 2.5~3.5 h, etc.

[0036] The specific conditions for reacting sodium 2-azidoglucose sulfinate with the RGD polypeptide are as follows: the RGD polypeptide and isothiazolone are dissolved in a mixed solution of water and acetonitrile, stirred for 5-15 min to allow the two to couple, then trifluoroacetic acid is added, and sodium 2-azidoglucose sulfinate and TBHP are added under an inert gas environment. The reaction is carried out at 20-30℃ for 4-8 h, and then purified by HPLC to obtain the 2N3-Glu-RGD intermediate.

[0037] The volume ratio of water to acetonitrile can be 1:1 to 1:3, preferably 1:2. The stirring time is preferably 8–12 min. Trifluoroacetic acid is typically added at 0.1%–1% of the total volume to maintain an acidic reaction environment. An inert gas environment is provided by nitrogen or argon. The reaction temperature is preferably 22–28°C, more preferably 25°C; the reaction time is preferably 5–7 h, more preferably 6 h. The conditions for HPLC purification are similar to those described above, and the target peak is collected and then lyophilized.

[0038] The solvent for the click cycloaddition reaction is a mixed solution of tert-butanol, water, and DMF, with a volume ratio of 0.5~1.5:0.5~1.5:0.5~1.5. More preferably, the volume ratio is 0.8~1.2:0.8~1.2:0.8~1.2, and most preferably 1:1:1. This mixed solvent system can simultaneously dissolve the hydrophobic TRAP chelating agent and the hydrophilic glycopeptide intermediate, ensuring a homogeneous reaction.

[0039] The click cycloaddition reaction further includes a copper removal purification step: DTPA is added to the reaction product, the pH is adjusted to 2.0~2.5 with hydrochloric acid, the reaction is heated to 50~70℃ for 0.5~2 h, and then preparative HPLC purification is performed.

[0040] DTPA, or diethylenetriaminepentaacetic acid, is a potent metal ion chelating agent used to capture residual copper ions during the reaction, preventing interference from copper ions in subsequent biological experiments. The pH is adjusted with hydrochloric acid, preferably to 2.2–2.3, more preferably 2.2. The heating temperature is preferably 55–65°C, more preferably 60°C; the reaction time is preferably 0.8–1.2 h, more preferably 1 h. After copper removal treatment, the blue color of the solution fades, indicating that the copper ions have been fully chelated. Further HPLC purification yields the metal ion-free target precursor.

[0041] Preferably, the method for preparing the radionuclide-labeled complex includes the following steps: dissolving the above compound, adjusting the pH of the reaction system to 2.5-4.5 using sodium acetate solution, adding the radionuclide solution, and heating the reaction at 70-90°C for 10-30 min to obtain the radionuclide-labeled complex.

[0042] The compound in question is the precursor Trap(Glu-RGD)3, which is typically stored as a lyophilized powder and dissolved in water for injection or a buffer solution before use. The sodium acetate solution is a 1 M aqueous solution used for precise pH adjustment; the pH is preferably 3.0–4.0, more preferably 3.5. The radionuclide solution can be… 68 GaCl3 solution (from) 68 Ge / 68 Ga generator rinsed) 177 LuCl3 solution or 161 TbCl3 solution. The reaction temperature is preferably 75~85℃, more preferably 80℃; the reaction time is preferably 15~25 min, more preferably 20 min. After the reaction is complete, no further purification is usually required, and the radiochemical purity can reach more than 95%, which can be directly used for in vivo experiments.

[0043] The present invention also provides a pharmaceutical composition comprising the above-described compound or a radiolabeled complex, and a pharmaceutically acceptable carrier.

[0044] The term "pharmaceutically acceptable carrier" refers to a diluent, excipient, or excipient that is applied to the target along with the active ingredient. It does not possess pharmacological activity itself but improves the stability, solubility, or ease of administration of the formulation. Common pharmaceutically acceptable carriers include, but are not limited to: water for injection, physiological saline, glucose solution, buffer solutions (such as phosphate buffer, acetate buffer), cyclodextrin, mannitol, sorbitol, trehalose, sucrose, lactose, starch, microcrystalline cellulose, hydroxypropyl methylcellulose, polyethylene glycol, polyvinylpyrrolidone, lecithin, Tween 80, Span, etc. The pharmaceutical compositions of this invention can be prepared into dosage forms such as injections, lyophilized powder injections, and sprays, with injections being the most commonly used. During preparation, the active ingredient can be dissolved in a sterile carrier, the pH and osmotic pressure adjusted, and after sterile filtration, dispensed into vials or freeze-dried for storage.

[0045] The present invention also provides the use of the above-mentioned compounds or radionuclide-labeled complexes in the preparation of imaging agents for tumor-targeted imaging.

[0046] The imaging agent, namely a positron emission tomography (PET) imaging agent or a single-photon emission computed tomography (SPECT) imaging agent, is used for the early diagnosis, staging, efficacy evaluation, and recurrence monitoring of integrin αvβ3-positive tumors. It is administered via intravenous injection, utilizing the specific binding of a probe to tumor angiogenesis and integrin αvβ3 on the surface of tumor cells, resulting in accumulation at the tumor site, which is then imaged using PET or SPECT equipment. Because the compound of this invention, after glycosylation modification, can penetrate the blood-brain barrier, it is particularly suitable for imaging central nervous system tumors such as gliomas. The imaging agent is usually supplied in sterile lyophilized powder form and should be used immediately before use. 68 Ga eluent was labeled and injected directly.

[0047] The present invention also provides the application of the above-mentioned radionuclide-labeled complex in the preparation of a drug for targeted radiotherapy of tumors.

[0048] When the radionuclide is 177 Lu or 161 At Tb, the complex of the present invention can be used as a targeted internal irradiation therapy drug. After intravenous injection, the radiotherapy drug specifically accumulates in tumor tissue, utilizing the β-particles emitted by the decay of the radionuclide to kill tumor cells. At the same time, due to the low uptake by normal tissues, the systemic radiation side effects can be reduced. 177 Lu-labeled RGD polymers have been shown to have good anti-tumor effects. This invention further reduces renal uptake through glycosylation modification, improving the therapeutic window and resulting in higher safety and efficacy. This therapeutic agent can be used to treat unresectable gliomas, bone metastases, and other integrin αvβ3-positive solid tumors, and can be used alone or in combination with chemotherapy and immunotherapy.

[0049] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0050] Example This embodiment provides radionuclide-labeled compounds. 68 The preparation method and preclinical application results of Ga]Ga-Trap(Glu-RGD)3 are as follows: 1. Synthesis of precursor compounds (1) Synthesis of TRAP chelating agent: Figure 2 To synthesize the TRAP chelating agent, S1 (1,4,7-triazacyclononane) and S2 (3-(hydroxyphosphoryl)propanoic acid) were dissolved in 6M hydrochloric acid aqueous solution. The solution was heated to 70°C, and paraformaldehyde solid was slowly added stepwise over 24 hours. The reaction progress was monitored by LCMS. The solution was evaporated to dryness and purified using a Dowex 50 wx8 ion exchange resin, eluted with pure water. Evaporation yielded a white solid S3 (TRAP intermediate). S3 was dissolved in DIPEA in DMSO and stirred for 10 min until clear. HATU and S4 (propargylamine) were added, and the mixture was stirred at 37°C for 30 min. The reaction was monitored by LCMS. The solvent was lyophilized, and 1 / 50 of a trifluoroacetic acid aqueous solution was added. A white solid precipitated, and the solution was allowed to stand for 3 hours, filtered, and purified by HPLC (15%-20% (MeCN / H2O)). The reaction was monitored by LCMS.

[0051] (2) Synthesis of sodium 2-azidoglucose sulfinate Figure 3 The synthetic route for sodium 2-azidoglucose sulfinate was as follows: 3a (6.13 g, 16 mmol) was placed in a flask, DCM was added to form a suspension, followed by Et3N (48 mmol, 6.65 mL), and finally chloroacetyl chloride (19.2 mmol, 1.82 mL). The reaction was carried out at room temperature for 2 h. The mixture was washed with saturated NaCl solution, the oil phases were combined, dried over anhydrous Na2SO4, concentrated under vacuum, and purified by flash column chromatography to obtain 3b (15.24 mmol, 6.45 g), with a yield of 95%.

[0052] Add 3b (3.35 g, 8 mmol) to a flask, dissolve in DMF, then add NaN3 (12 mmol, 780 mg), and react at room temperature for about 3 h. Quench with NaHCO3 aqueous solution, then add petroleum ether, wash the oil phase with semi-saturated NaCl solution, dry with anhydrous Na2SO4, and concentrate under vacuum, proceeding directly to the next step. Combine the aqueous phases and quench with PPh3.

[0053] 3c (8 mmol, 3.44 g) was added to a flask, dissolved in DCM, and then BF3·Et2O (16 mmol, 2.03 mL) and methyl mercaptopropionate (9.6 mmol, 1.07 mL) were added dropwise. The mixture was stirred at room temperature for approximately 3 h. The mixture was quenched with excess NaHCO3, washed three times with saturated NaCl solution, dried over anhydrous Na2SO4, and the oil phase was concentrated under vacuum. The oil phase was then purified using a flashcolumn to yield 3d (4.6 mmol, 2.25 g), with a yield of 57.5%.

[0054] 3d (2.3 mmol, 1.13 g) was added to a flask, dissolved in DCM, and the temperature was lowered to 0 °C. Then, mCPBA (8.05 mmol, 0.66 g) was added, and the mixture was allowed to return to room temperature. The reaction was carried out at room temperature for 3 h. The reaction was quenched with NaHCO3 and Na2S2O3 solutions, washed three times with saturated NaCl solution, dried over anhydrous Na2SO4, and the oil phase was concentrated under vacuum. The oil phase was then separated and purified using a flash column to obtain 3e 2.3 mmol, 1.16 g, with a yield of 95%.

[0055] Add 3e (1.1 mmol, 0.58 g) to a flask, add MeOH to form a suspension, then add MeONa (1.1 mmol, 59.4 mg), and react at room temperature for about 2 h. Rotate the mixture to dryness, then add 1 mL of methanol, and add 100 mL of DCM while sonicating. Finally, filter the mixture in a glove box and wash with ultra-dry DCM.

[0056] (3) Preparation of 2N3-Glu-RGD Figure 4The synthetic route for 2N3-Glu-RGD was as follows: c(RGDfK) (a peptide, as shown in SEQ ID NO.1) and KIT (isothiazolone, used to form disulfide bonds with the free thiol groups of the peptide for further radical reactions) were dissolved in a water / acetonitrile mixture until clear, and stirred for ten minutes (LCMS monitoring showed disappearance of the starting material and formation of the coupling product). Trifluoroacetic acid was added, followed by the addition of S3 and TBHP under N2 atmosphere. The reaction was carried out at room temperature for 6 hours, and LCMS monitoring showed complete reaction. The final product was purified by HPLC (20% MeCN / H2O).

[0057] (4) Preparation of Trap(Glu-RGD)3 Figure 5 The synthetic route for Trap(Glu-RGD)3 was as follows: Under N2 atmosphere, 2N3-Glu-RGD, TRAP chelating agent, [Cu(MeCN)4]PF6, and ligand were dissolved in a 1:1:1 solution of tert-butanol / water / DMF and reacted at 60°C for 10 hours, with LCMS monitoring the reaction progress. Four click reactions were performed stepwise. The product was purified by HPLC (25% MeCN / H2O). The purified product was a copper ion complex; DTPA was added, and the pH was adjusted to 2.2 with 1M hydrochloric acid aqueous solution. The reaction was heated to 60°C for 1 hour, and the blue color of the solution faded, as monitored by LCMS. The mixture was filtered, purified by HPLC (25% MeCN / H2O), and lyophilized to a white solid.

[0058] 2. 68 Ga radiolabeling from 68 Ge / 68 Ga is obtained by rinsing in a Ga generator 68 GaCl3 solution. Dissolve 50 μg of Trap(Glu-RGD)3 precursor in a 4 mL quartz reaction flask. Adjust the pH of the mixture to 3.0–4.0 using 1 M sodium acetate solution, then heat at 80°C for 20 minutes. No further purification is required to obtain [ 68 Ga]Ga-Trap(Glu-RGD)3.

[0059] 3. Quality Control The labeled products were analyzed using radio-high performance liquid chromatography (Radio-HPLC). The results showed that ( Figure 6 The compound exhibited a UV absorption peak retention time of 5.89 min at 254 nm and a corresponding radioactive peak retention time of 6.05 min, indicating good chemical consistency of the labeled product. The radiochemical purity was determined to be 99.84%, with no significant free radioactive components detected. 68 Ga or byproduct peaks indicate that the TRAP chelation system is effective against these peaks. 68Ga exhibits extremely high coordination efficiency and stability.

[0060] 4. Stability Evaluation Get 3.7 MBq [ 68 Ga]Ga-Trap(Glu-RGD)3 (100 μL) was added to equal volumes of PBS buffer (pH 7.4) and fetal bovine serum (FBS), respectively, and incubated at 37°C. Radiochemical purity was detected at different time points (0, 15, 30, 60, and 120 min), and analysis was performed using radio-high performance liquid chromatography (Radio-HPLC). The results showed that ( Figure 7 A single main peak was observed at different time points, and no obvious degradation products were observed, indicating that the probe has good in vitro stability in PBS and FBS systems. At 120 min, its radiochemical purity remained above 99.50% in PBS and above 99.34% in FBS, and no obvious delabeling or radiation degradation was observed.

[0061] 5. Micro-PET / CT imaging Imaging studies were conducted on U87MG glioma-bearing mice (n = 3) using the Inviscan IRIS small animal PET / CT system. The tumors were implanted via tail vein injection. 68 Ga]Ga-Trap(Glu-RGD)3 (3.7 MBq / mouse) was administered via Ga-Trap(Glu-RGD)3 at 0.25, 0.5, 1, and 2 h post-injection, followed by static scanning. In the blocking imaging experiment, mice were first injected via tail vein 30 min prior to injection with the c(RGDfK) targeting peptide (200 μg / mouse) to competitively block the integrin αvβ3 receptor, followed by injection via tail vein... 68 [Ga]Ga-Trap(Glu-RGD)3 (3.7 MBq / mouse) was administered, and static PET / CT scans were performed at 0.25, 0.5, 1, and 2 h post-injection to assess the probe's specific uptake. Mice were kept under 2% isoflurane anesthesia during the scans, with each acquisition session lasting 15 min. Image reconstruction was performed using the 3D ordered subset expectation-maximization (3D-OSEM) algorithm, and quantitative analysis was performed using OsiriX MD software. The radioactive uptake value (%ID / g) was calculated by delineating regions of interest (ROIs) in the tumor and major organ regions.

[0062] In vivo PET / CT imaging results showed that ( Figure 8 ), [ 68Ga]Ga-Trap (Glu-RGD)3 exhibited excellent tumor targeting ability and favorable pharmacokinetic characteristics in vivo. The probe rapidly distributed throughout the systemic circulation after administration, with significant radioactive enrichment observed at the tumor site as early as 15 min. Over time, radioactivity was gradually cleared from the blood and non-target tissues, while the signal persisted at the tumor site, thus continuously improving the contrast between the tumor and background. Although tumor and renal uptake gradually decreased over time, the tumor still maintained a high uptake level (4.8% ID / g) at 120 min, indicating good tumor retention capacity of the probe. Furthermore, rapid renal radioactivity clearance was beneficial in reducing radiation burden on non-target organs.

[0063] Notably, this probe effectively penetrates the blood-brain barrier, achieving specific enrichment in an orthotopic glioma model, while exhibiting low uptake in normal brain tissue, demonstrating an excellent tumor / normal brain tissue ratio (T / NT) and significantly improving imaging contrast. Figure 9 The above results indicate that the probe described in this invention has good application potential and clinical translational value in tumor imaging, especially in molecular imaging of gliomas.

[0064] To evaluate [ 68 The specific binding ability of Ga]Ga-Trap(Glu-RGD)3 to the integrin αvβ3 receptor was investigated using imaging techniques to block the receptor. Competitive blocking of the receptor was achieved by intravenous injection of an excess of c(RGDfK) peptide 30 min prior to the receptor, and the results were compared with the unblocked group. Micro-PET / CT imaging results ( Figure 10 A) shows that in the blocking group, radioactive uptake in the tumor region was significantly reduced, and the signal in the area marked by the red dashed line was significantly weakened, suggesting that probe uptake in the tumor mainly depends on the specific binding of integrin αvβ3. Semi-quantitative analysis results of the region of interest (GRI) Figure 10 B) This further validated the above observations. At each time point (15, 30, 60, and 120 min), tumor uptake in the blocking group was significantly lower than that in the non-blocking group (p < 0.0001). Specifically, tumor uptake in the non-blocking group remained within the range of approximately 3.5–4.5 %ID / g, while it decreased in the blocking group to approximately 1.0–2.0 %ID / g, with an overall decrease of approximately 50%–70%. Meanwhile, the change in uptake in non-target tissues after blocking was relatively small, further indicating that the reduction in tumor signaling mainly stemmed from the inhibition of specific binding, rather than a change in overall distribution.

[0065] In summary, the results of the blocking experiment clearly show that [ 68Ga]Ga-Trap (Glu-RGD)3 exhibits high specificity for the integrin αvβ3 receptor, and its tumor uptake is primarily mediated by the interaction between the RGD sequence and integrin. Notably, glycosylation modification effectively optimizes the in vivo distribution behavior of the probe without weakening its receptor binding ability, providing strong support for its application in tumor molecular imaging and potential radiotherapy.

[0066] 5. In vivo distribution study U87MG glioma-bearing mice were randomly divided into groups (n = 3 per group) and injected with 100 μL via the tail vein. 68 Ga]Ga-Trap(Glu-RGD)3 (1.11 MBq). Animals were sacrificed at 0.25, 0.5, 1, and 2 h post-injection, and tumors and major organs, including blood, heart, liver, spleen, lungs, kidneys, stomach, intestines, muscles, bones, and brain tissue, were collected. Radioactivity of each tissue was determined using an automated gamma counter (Wizard, PerkinElmer, USA) and corrected for decay. Results are expressed as percentage of injected dose per gram of tissue (%ID / g).

[0067] The results show that ( Figure 11 ), and unglycosylated [ 68 Compared to Ga-Trap(RGD)3, [ 68 Ga-Trap (Glu-RGD)3 increased tumor uptake by approximately 17% and significantly decreased renal uptake by approximately 47% at 60 min, thereby increasing the tumor / kidney ratio by approximately 128%, significantly improving the in vivo distribution characteristics of RGD drugs and reducing potential non-target organ toxicity. Furthermore, [ 68 At 120 min, the tumor uptake of Ga]Ga-Trap(Glu-RGD)3 remained at 5.62% ID / g, further demonstrating its good tumor retention ability and potential therapeutic value.

[0068] Figure 12 This is the high-resolution electrospray ionization mass spectrometry (HRMS, ESI-TOF) spectrum of Trap(Glu-RGD)3. This compound exhibits typical multi-charged ion peaks in positive ion mode, with [M+2H] as an example. 2+ The theoretical calculated value is 1749.2182, and the measured value is 1749.2206; [M+3H] 3+ The theoretical calculated value is 1166.4813, and the measured value is 1166.4811; [M+4H] 4+The theoretical calculated value was 875.1128, and the measured value was 875.1119. This indicates that the synthesized product is the target compound Trap(Glu-RGD)3, and the purity meets the experimental requirements.

[0069] As shown in the above embodiments, this invention provides a radioactive RGD multivalent ligand based on a TRAP chelating agent and glucose modification, along with its preparation method and applications. Small animal PET / CT imaging and in vivo distribution experiments confirmed that this probe can efficiently target integrin αvβ3-positive tumors and achieve long-term retention at the tumor site. Glycosylation modification significantly reduces non-specific uptake of the probe in the kidneys while endowing it with the ability to penetrate the blood-brain barrier, resulting in clear imaging of in situ glioma lesions. Blocking experiments further verified the targeting specificity of the probe. Furthermore, the probe has a simple preparation process, high labeling yield, and good in vitro stability, possessing the potential to be transformed into a clinical tumor imaging agent and laying the foundation for subsequent research on therapeutic radionuclides for integrated diagnosis and treatment.

[0070] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A compound, characterized in that, The compound is compound A or a pharmaceutically acceptable salt thereof, wherein compound A has the following structure: a TRAP chelating agent as the core backbone, wherein each of the three branches of the TRAP chelating agent is connected to a glucose-modified RGD polypeptide unit via a triazole ring, wherein the TRAP chelating agent is triazacyclononane-trimethylenephosphonic acid, and the glucose modification is to attach a 2-azidoglucose group to the lysine residue of the RGD polypeptide; The RGD polypeptide is a cyclic polypeptide containing the amino acid sequence shown in SEQ ID NO:1; The compound A has the structure shown in Formula I: Equation I.

2. A radionuclide-labeled complex, characterized in that, The complex is formed by coordination between the compound of claim 1 and a radionuclide, wherein the radionuclide is selected from... 68 Ga、 177 Lu or 161 At least one of Tb.

3. The method for preparing the compound according to claim 1, characterized in that, Includes the following steps: Synthesize sodium 2-azidoglucose sulfinate; The RGD peptide and isothiazolone were dissolved in a mixed solution of water and acetonitrile. After stirring and reacting, trifluoroacetic acid was added, and sodium 2-azidoglucose sulfinate and TBHP were added under an inert gas atmosphere to obtain the 2N3-Glu-RGD intermediate. Under inert gas protection, the 2N3-Glu-RGD intermediate and the TRAP chelating agent were reacted with a copper catalyst and ligand at 60-80°C for 8-12 h to carry out a click cycloaddition reaction to generate the compound.

4. The preparation method according to claim 3, characterized in that, The TRAP chelating agent is prepared by a method including the following steps: dissolving compound 1,4,7-triazacyclononane and 3-(hydroxyphosphono)propionic acid in hydrochloric acid aqueous solution, heating to 60~80℃, adding paraformaldehyde stepwise over 18~30 h, and obtaining the TRAP intermediate after purification by ion exchange resin. The TRAP intermediate and DIPEA were dissolved in DMSO, HATU and propargylamine were added, and the mixture was stirred at 30-40°C for 20-40 min. Then, trifluoroacetic acid aqueous solution was added to precipitate the solid, which was purified by HPLC to obtain the TRAP chelating agent. The sodium 2-azidoglucose sulfinate is obtained by a preparation method including the following steps: reacting a starting glucose intermediate with chloroacetyl chloride at 20-30°C for 1-3 h in the presence of dichloromethane and triethylamine to obtain intermediate product 1; The intermediate product 1 was reacted with sodium azide in DMF at 20-30°C for 2-4 h to obtain intermediate product 2; The intermediate product 2 was reacted with methyl mercaptopropionate at 20-30°C for 2-4 h under BF3·Et2O catalysis to obtain intermediate product 3; mCPBA was added at 0~5℃, and then the temperature was restored to 20~30℃ for 2~4 h to oxidize intermediate 3 to intermediate 4. The intermediate product 4 was reacted in the presence of MeONa at 20-30°C for 1-3 h to remove the acetyl protecting group, yielding sodium 2-azidoglucose sulfinate. The specific conditions for reacting sodium 2-azidoglucose sulfinate with the RGD polypeptide are as follows: the RGD polypeptide is dissolved in a mixed solution of water and acetonitrile, stirred for 5-15 min, trifluoroacetic acid is added, sodium 2-azidoglucose sulfinate and TBHP are added under an inert gas environment, and the reaction is carried out at 20-30℃ for 4-8 h. Then, the intermediate 2N3-Glu-RGD is obtained by HPLC purification. The solvent for the click cycloaddition reaction is a mixed solution of tert-butanol, water, and DMF, with a volume ratio of 0.5~1.5:0.5~1.5:0.5~1.

5. The click cycloaddition reaction further includes a copper removal purification step: DTPA is added to the reaction product, the pH is adjusted to 2.0~2.5 with hydrochloric acid, the reaction is heated to 50~70℃ for 0.5~2 h, and then preparative HPLC purification is performed.

5. The method for preparing the radionuclide-labeled complex according to claim 2, characterized in that, The process includes the following steps: dissolving the compound according to claim 1, adjusting the pH of the reaction system to 2.5-4.5 using sodium acetate solution, adding a radionuclide solution, and heating the reaction at 70-90°C for 10-30 min to obtain the radionuclide-labeled complex.

6. A pharmaceutical composition, characterized in that, It comprises the compound of claim 1 or the radiolabeled complex of claim 2, and a pharmaceutically acceptable carrier.

7. The use of the compound of claim 1 or the radionuclide-labeled complex of claim 2 in the preparation of imaging agents for tumor-targeted imaging.

8. The use of the radionuclide-labeled complex of claim 2 in the preparation of a medicament for targeted radiotherapy of tumors.